-The Hindu ICAR “shielding errant officials” by delaying the report In a damning indictment of the way some Bt cotton varieties were developed and commercialised in the country, a committee headed by Prof. S.K. Sopory, Vice-Chancellor of JNU, found that indigenous Bikaneri Nerma (BN) Bt cotton variety was contaminated by a gene patented by Monsanto. Having found lapses in the “BNLA106 event”, the committee has held as “invalid” the data obtained from bio-safety...

-The Wall Street Journal   While modern crop engineering faces endless red tape, more slipshod cross-breeding gets a free pass. India has enjoyed signal successes with genetic engineering in agriculture. But today the nation's relationship with this critical biotechnology is in total disarray, the victim of activists' scaremongering and government pandering. Delhi should know better. Following the adoption of the genetically improved varieties and intensive crop management practices of the Green Revolution, from 1960...

-Live Mint The first in a two-part series examining the opaque world of clinical trials in India  A hospital in Indore has been able to get away with unethical medical trials in which 32 people have died over five years, according to the state government. This despite several investigations, a state government ban and Supreme Court strictures—a classic example of the lawless nature of the clinical trial business in India.   Lata Mehra, who...

-The Economic Times Drug companies paid as little as 50,000 as compensation to families of volunteers who died during clinical trials for new medicines last year, leading to sharp criticism about the paltry sums being handed out and growing clamour among health groups for more stringent guidelines on new drug trials.  According to government data accessed by a healthcare activist through an RTI query, Germany's Fresenius Kabi paid 50,000 each to the...

-The Economic Times It's not just the drug regulator, where a parliamentary panel has alleged corruption, failing in its job. Drug regulation across entities that dot this broad landscape is in poor health and ineffective. In May, when a Parliamentary panel, during a routine examination of healthcare regulatory bodies, alleged corruption in the approval of new drugs, it was merely pointing out one symptom. Such symptoms pervade the entire drug regulation landscape,...